Individualized Dose-Response to Statins Associated With Cardiovascular Disease Outcomes
Authors' conclusion
The class-wide association of ED50 and Emax with clinical outcomes indicates that these measures influence the risk for ASCVD events in patients on statins.
Study context
- Population
- Individuals exposed to multiple doses of atorvastatin, simvastatin or rosuvastatin, de-identified electronic health records
- Participants
- 3,033 individuals
- Exposure
- Individualized statin dose-response and atherosclerotic cardiovascular disease (ASCVD) outcomes
- Atorvastatinn = 1,632
- Simvastatinn = 1,089
- Rosuvastatinn = 312
- Outcome
- Composite of:
- ASCVD events
- All-cause mortality
Methodological detailselectronic health record data
- Electronic health record data
Main finding
As reported in the abstract
- Atorvastatin · ED50
- HR 0.85; P < 0.01
- Simvastatin · ED50
- HR 0.83; P < 0.01
- Rosuvastatin · ED50
- HR 0.87; P = 0.10
- Atorvastatin · Emax
- HR 1.13; P < 0.001
- Simvastatin · Emax
- HR 1.06; P < 0.001
- Rosuvastatin · Emax
- HR 1.15; P = 0.009
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Individualized Dose-Response to Statins Associated With Cardiovascular Disease Outcomes. JACC Adv. Published 7 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →